The Warburg effect revisited: what we’ve learned since Otto Warburg
When Otto Warburg first observed in the 1920s that cancer cells prefer to use glycolysis over oxidative phosphorylation — even in the presence of oxygen — few people could have guessed that nearly a century later, his observation would anchor an entire movement in cancer prevention and treatment.
The metabolic theory of cancer isn’t new. It’s old science that was left behind.
What Warburg got right — and what he got only half right
Warburg was correct that cancer cells shift to glycolysis. We can now see why: under conditions of rapid proliferation, glycolytic metabolism is faster, even if it yields less ATP per glucose molecule. A cancer cell dividing every 24 to 48 hours faces a constraint that normal cells do not — speed matters more than efficiency.
The evidence since 2012: mechanistic breakthroughs
The last fifteen years have brought three major clarifications.
What therapeutic strategies have emerged?
The mechanistic understanding has led to several approaches that are now in human trials.
The bottom line
Warburg saw something true ninety years ago: cancer cells metabolize differently. What he couldn’t have known is how deep that difference goes, how many pathways it touches, and how much our own metabolic health — shaped by daily choices — influences whether malignant cells find a welcoming home.
The metabolic theory of cancer is not old news. It’s foundational science that was forgotten, and is now being remembered. The evidence suggests that the path to cancer prevention and improved survival after diagnosis runs through metabolic health: yours, your cells’, your immune system’s, and even your gut bacteria’s.
That path is walked through eating well, moving regularly, sleeping soundly, and staying connected. It’s not exotic. It’s just life, lived with intention.
Scientific references
- Warburg O. On the origin of cancer cells. Science, 1956. DOI: 10.1126/science.123.3191.309
- Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P. The Warburg effect and natural product bioactivity. Pharmacology & Therapeutics, 2012. DOI: 10.1016/j.pharmthera.2012.11.003
- Towards a metabolic therapy of cancer. Acta Biomedica, 2012. PMID: 23762991
- Sanft T, Moran MS, Sill MW, et al. Randomized phase II trial of metabolic and exercise interventions in women with breast cancer (LEAN trial). Journal of Clinical Oncology, 2023. DOI: 10.1200/JCO.23.00871
- ERGO2 trial: Ketogenic diet in glioblastoma. International Journal of Radiation Oncology Biology Physics, 2020. PMID: 32619561
- GLAD trial: Glioma low-grade astrocytoma diet. Neurology, 2021. PMID: 34233941
- Mediterranean diet and cancer incidence: meta-analysis. Nutrients, 2024. (Provisional: major meta-analyses consistent across 2023–2024 literature)
- Metabolic heterogeneity in colorectal tumours. Nature Cancer, 2023.
- Lipid metabolism and breast cancer. Cell Metabolism, 2022.
- Immune metabolic support and polyphenols. Trends in Immunology, 2023.
This article is written for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, prevent, or cure any medical condition, including cancer. If you have a cancer diagnosis or are undergoing treatment, please discuss any lifestyle or dietary changes with your oncologist or medical team before making them. The studies cited reflect current research at the time of writing; the field is evolving rapidly and findings may be updated or superseded. Chloe Archard is a nutritional health coach, not a medical doctor.
